Aaron Logan, MD, PhD, MPhil
banner
hemedoc.bsky.social
Aaron Logan, MD, PhD, MPhil
@hemedoc.bsky.social
Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, HLH, MRD, post-HCT relapse, GVHD, & immune recon. Photos (Instagram): pyknosis
Those in MAGA land who voted for this administration don’t realize that these changes will cause hospitals in their small communities to close. Not only will they not have health insurance; they won’t even have ER level care in their communities.
August 29, 2025 at 3:15 AM
Many of my pts are undoc’d and I hv always been proud of CA for giving them Medi-Cal coverage (CA v of Medicaid). W/o Medicaid $ I don’t know if this can continue .. unless we revolt stop sending so much tax $ to the Fed. But this isn’t just undoc’d — others will also lose access to insurance. Evil.
August 29, 2025 at 3:15 AM
Lack of auto-renewal is also meant to uninsure more Americans.
August 29, 2025 at 3:15 AM
Imgs from @johnshopkinssph.bsky.social on IG. In my experience, essentially all people want to work when their health allows. But not everyone can find a job. Making monthly work assessments part of maintaining bare minimum health insurance is a ruse to uninsure more Americans. Disgusting.
August 29, 2025 at 3:15 AM
July 22, 2025 at 3:06 AM
“Working” with ChatGPT is like having an emotionally abusive partner. (Hey OpenAI: the fabrication of references problem has been known for a long time now. Preventing your bot from creating fake references with real PMID numbers that are verifiably wrong with one click should be easy…)
July 6, 2025 at 4:42 PM
#ASCO25 is going great so far. I love how walkable Chicago is day and night this time of year. Seriously, if anyone knows a place that has the same vibe and weather as late May in Chicago — but year-round — please let me know, because I want to move there!
May 31, 2025 at 5:26 AM
#ASCO25 Arce-Ruiz: identified ~30K w CH vs 440K wo CH in Biobank DB. Age-related macular degeneration (AMD) appears to be modestly assoc w CH (HR 1.15) but no specific gene mutation indicted as culprit. CH not assoc w vision loss in those with AMD.
May 30, 2025 at 7:25 PM
#ASCO25 #mpnsm Arce-Ruiz: Macular degeneration in pts w clonal hematopoiesis.
May 30, 2025 at 7:21 PM
#ASCO25 #mpnsm Andorsky: Asciminib in 2L CML (wo T315I), n=101, treatment ongoing in 91%. 82.5% achieved BCR-ABL <0.1%, 44% MMR at 24wks. Only 3% had AEs leading to discontinuation. Study ongoing.
May 30, 2025 at 7:19 PM
#ASCO25 #mpnsm Andorsky: Asciminib in 2L treatment of CML (wo T315I). Reason for dc 1L TKI was lack of efficacy in 57% and intolerance 43%.
May 30, 2025 at 7:14 PM
#ASCO25 #mpnsm Mascarenhas: Imetelstat + Ruxolitinib in Int1/2- and HR-MF. Combo well tolerated with low incidence of tcp. Significant redxn in sx burden and spleen size. Also decreased VAF of driver mutations w combo at Imetelstat RP2D.
May 30, 2025 at 7:10 PM
#ASCO25 #mpnsm Mascarenhas: Imetelstat + Ruxolitinib in Int1/2- and HR-MF.
May 30, 2025 at 7:06 PM
#ASCO25 #leusm Goldfinger: Metronomic (weekly) DAC/Ven appears favorable in TP53m MDS/AML vs historical controls (~1/3 of whom recd conventional HMA/Ven). Low rate (12.5%) of febrile neutropenia with metronomic dosing.
May 30, 2025 at 6:52 PM
#ASCO25 #leusm Goldfinger: Metronomic (weekly) DAC/Ven in TP53m MDS/AML. Median OS 11mos. Responses probably (small n) better with monoallelic TP53m.
May 30, 2025 at 6:49 PM
#ASCO25 #leusm Goldfinger: Dosing Decitabine and Ven for terminal differentiation in MDS/AML. Typical dosing relies on TP53 activity. Metronomic dosing (once weekly for both DAC/Ven) may be TP53 independent. Prelim data favorable. Today presenting data on those w TP53m.
May 30, 2025 at 6:46 PM
#ASCO25 #mdssm Daver: Bexmarilimab in HR-MDS has excellent safety profile (13% dc for TEAE, IrAEs in 4%). ORR 72% in 1L, 63% in relapse. Encouraging responses in TP53m setting as well.
May 30, 2025 at 6:42 PM
#ASCO25 #mdssm Daver: Macrophage checkpoint Clever-1 inhibition with Bexmarilimab (w Aza) in HR-MDS. Clever-1 involved in conversion of macrophage to pro-inflammatory phenotype.
May 30, 2025 at 6:39 PM
#ASCO25 #mdssm Garcia-Manero: transfusion independence 76% with Luspa vs 56% with epo with median DOR and 150 vs 95wks. Median OS not NR with Luspa yet vs 46mo with Epo.
May 30, 2025 at 6:35 PM
#ASCO25 #mdssm Garcia-Manero: survival and duration of response update (median f-up >2.5yr) on COMMANDS trial of Luspatercept vs Epo in LR-MDS. Median tx duration 71.5 vs 44 wks.
May 30, 2025 at 6:31 PM
#ASCO25 #leusm Desai: lower dose PTCy assoc with fewer bloodstream infections — 30% vs 59% at D30 — and fewer CMV reactivations — 19% vs 7% at D100. Also less volume overload (fluid toxicity) with lower dose PTCy.
May 30, 2025 at 6:27 PM
#ASCO25 #leusm Desai: lower dose PTCy (70) assoc with slightly faster engraftment and no diff in GVHD incidence vs standard (100).
May 30, 2025 at 6:24 PM
#ASCO25 #leusm Desai: Reduced dose PTCy (70 v 100mg/m2) after allo for AML using MUD. PTCy reduces GVHD but will assoc w high infxn risk. This single center study evald lower total Cy dose (with low dose ATG).
May 30, 2025 at 6:22 PM
#ASCO25 #leusm Aldoss: MRD negativity after end of induction with chemo+Ponatinib on PhALLCON trial. 56% w Ponat vs 69% with Imat not MRD neg at EOI. In those not MRD neg at EOI, superior OS in those receiving Ponat.
May 30, 2025 at 6:14 PM
#ASCO25 #leusm Luskin: Asciminib+Dasatinib+Pred+Blin for newly dx Ph+ ALL. No relapses this far.
May 30, 2025 at 6:08 PM